Chronic lymphocytic leukemia and mantle cell lymphoma

Chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) are cancers of B-cells that share epidemiological characteristics, molecular alterations, and clinical features but which differ from other lymphoid neoplasms. Clinical development of both tumor types is very heterogeneous, with subsets of patients having stable disease for a long time, whereas, others, sadly require immediate intervention.

Patients are currently treated with successive rounds of therapy and often develop refractory disease as there are currently no curative therapies.

Approximately 21,000 and 4,200 people respectively are diagnosed with CLL and MCL annually in the United States.

More in this section


NovalGen is focused on bispecific antibody treatment.

Read more

Clinical trials

NovalGen is committed to developing innovative treatments.

Read more